Agilent Technologies (NYSE:A) PT Lowered to $135.00

Agilent Technologies (NYSE:A – Get Rating) had its target price dropped by analysts at Stifel Nicolaus from $153.00 to $135.00 in a research note issued on Wednesday, The Fly reports. The brokerage currently has a “hold” rating on the medical research company’s stock. Stifel Nicolaus’ price objective indicates a potential upside of 12.98% from the stock’s previous close.

Other equities analysts have also recently issued reports about the stock. Robert W. Baird reduced their price target on shares of Agilent Technologies from $174.00 to $144.00 and set an “outperform” rating on the stock in a research report on Wednesday. Credit Suisse Group lowered their price target on shares of Agilent Technologies from $170.00 to $160.00 and set an “outperform” rating on the stock in a research note on Wednesday. Citigroup lowered their price objective on shares of Agilent Technologies from $150.00 to $130.00 and set a “neutral” rating on the stock in a research note on Wednesday. StockNews.com began coverage on shares of Agilent Technologies in a research note on Thursday, May 18th. They issued a “buy” rating on the stock. Finally, Wells Fargo & Company cut their price target on shares of Agilent Technologies from $170.00 to $160.00 and set an “overweight” rating for the company in a report on Wednesday. Three research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $151.35.

Agilent Technologies Stock Down 1.2 %

Shares of A opened at $119.49 on Wednesday. The stock has a market cap of $35.33 billion, a price-to-earnings ratio of 26.32, a P/E/G ratio of 1.89 and a beta of 1.03. The company has a 50-day moving average price of $133.52 and a two-hundred day moving average price of $143.94. The company has a quick ratio of 1.53, a current ratio of 2.11 and a debt-to-equity ratio of 0.49. Agilent Technologies has a 12 month low of $112.52 and a 12 month high of $160.26.

Agilent Technologies (NYSE:A – Get Rating) last posted its quarterly earnings data on Tuesday, May 23rd. The medical research company reported $1.27 earnings per share for the quarter, topping the consensus estimate of $1.26 by $0.01. The company had revenue of $1.72 billion during the quarter, compared to analyst estimates of $1.67 billion. Agilent Technologies had a net margin of 19.19% and a return on equity of 30.74%. The company’s revenue was up 6.8% on a year-over-year basis. During the same quarter last year, the business posted $1.13 earnings per share. Equities analysts predict that Agilent Technologies will post 5.68 EPS for the current fiscal year.

Institutional Investors Weigh In On Agilent Technologies

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Financial Gravity Asset Management Inc. bought a new position in Agilent Technologies in the first quarter worth approximately $2,108,000. Money Concepts Capital Corp acquired a new stake in shares of Agilent Technologies during the 4th quarter valued at about $26,000. Delta Asset Management LLC TN acquired a new stake in shares of Agilent Technologies during the 4th quarter valued at about $26,000. Mitsubishi UFJ Morgan Stanley Securities Co. Ltd. acquired a new stake in Agilent Technologies in the 4th quarter worth about $27,000. Finally, Newbridge Financial Services Group Inc. lifted its stake in Agilent Technologies by 217.6% in the 4th quarter. Newbridge Financial Services Group Inc. now owns 216 shares of the medical research company’s stock worth $32,000 after purchasing an additional 148 shares in the last quarter. 85.51% of the stock is currently owned by hedge funds and other institutional investors.

Agilent Technologies Company Profile

(Get Rating)

Agilent Technologies, Inc engages in the provision of application focused solutions for life sciences, diagnostics, and applied chemical markets. It operates through the following segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers application-focused solutions that include instruments and software that identify, quantify, and analyze the physical and biological properties of substances and products, as well as the clinical and life sciences research areas to interrogate samples at the molecular and cellular level.